Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "Caplin"

35 News Found

Caplin Steriles gets USFDA approval for Thiamine Hydrochloride Injection
Drug Approval | March 09, 2023

Caplin Steriles gets USFDA approval for Thiamine Hydrochloride Injection

Thiamine Hydrochloride Injection is effective in the treatment of vitamin B1 deficiency (beriberi)


Caplin Steriles gets USFDA approval for Rocuronium Bromide Injection
Drug Approval | March 04, 2023

Caplin Steriles gets USFDA approval for Rocuronium Bromide Injection

Rocuronium Bromide Injection is a neuromuscular blocking agent


Caplin Point’s Q3 in line; outlook positive amid expansion plans: ICICI Direct
News | February 07, 2022

Caplin Point’s Q3 in line; outlook positive amid expansion plans: ICICI Direct

Key takeaways of recent quarter & conference call highlights


Caplin Point Q3FY22 PAT at Rs 74.95 cr.
News | February 03, 2022

Caplin Point Q3FY22 PAT at Rs 74.95 cr.

Caplin Point Laboratories has reported consolidated financial results for the period ended December 31, 2021.


Caplin Point Labs posts  Q2FY22 PAT at Rs 74.98 Cr
News | November 02, 2021

Caplin Point Labs posts Q2FY22 PAT at Rs 74.98 Cr

The Board of Directors of Caplin Point Laboratories at its meeting have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021


Caplin Steriles gets US FDA approval for blood pressure injection
News | September 08, 2021

Caplin Steriles gets US FDA approval for blood pressure injection

Labetalol hydrochloride injection USP is indicated for the control of blood pressure in severe hypertension.


Caplin Point Lab's subsidiary receives nod from Brazil's ANVISA for sterile injectable manufacturing site
Drug Approval | August 17, 2021

Caplin Point Lab's subsidiary receives nod from Brazil's ANVISA for sterile injectable manufacturing site

The approval allows it to market its products in the country


Caplin Point Laboratories posts consolidated PAT in Q1FY22 at Rs 70.85 Cr
News | August 05, 2021

Caplin Point Laboratories posts consolidated PAT in Q1FY22 at Rs 70.85 Cr

EPS climbs to Rs 9.25 for the quarter


Caplin gets USFDA approval for Sumatriptan
News | July 15, 2021

Caplin gets USFDA approval for Sumatriptan

Sumatriptan Injection USP is indicated in adults for acute treatment of migraine with or without aura, and acute treatment of cluster headache


Caplin Steriles gets USFDA approval
News | April 23, 2021

Caplin Steriles gets USFDA approval

The injection comes in multiple formats